---
title: "a-Synuclein Aggregates in Parkinson’s Disease"

subtitle: "SAA Analysis from PPMI Projects 155 & 237"

author: 
  - name: "Malaika Khiljee"
  - name: "Karolina Nordkamp"
  - name: "Isabella Christoffersen"
  - name: "Andreas Nielsen"

date: "2 December 2025"

format:
  revealjs: 
    theme: simple
    slide-number: true
    center: false
    scrollable: true
    transition: fade
    transition-speed: fast
---

```{=html}
<style>
/* tekststørrelsen på teksten i slides */
.reveal, .reveal .slides {
  font-size: 1.40rem !important;   
}

/* kode-font større */
.reveal pre code {
  font-size: 1.1rem !important;
  line-height: 1.2 !important;
}


/* TIL TABELLER! */   

.reveal .slides section table {
  width: 100% !important;                   /* gør så at tabellen fylder hele slidet */
  border-collapse: separate !important;
  border-spacing: 0 !important;
  border: 1px solid #999 !important;         /* gør så at der er kant om tabel */
  border-radius: 6px !important;
  overflow: hidden !important;
  margin-left: 0 !important;
  margin-right: 0 !important;
}

 /* skriftstørrelse på tabellerne */
.reveal table {
  font-size: 1.2rem;
}

.reveal table th {
  font-size: 1.1rem;
}

/*afstand mellem tabeller */
.reveal .slides section table + table {
  margin-top: 2rem !important;   /* justér som du vil */
}

/* venstrejusteret tabel */
.reveal .slides section table {
  margin-left: 0 !important;     
  margin-right: auto !important;
  display: table !important;
  text-align: left !important;  
}

/*ændrer i tabel header*/
.reveal .slides section table th {
  background: #b6b6cf !important;
  font-weight: 700 !important;
  padding: 10px 12px !important;
  border-bottom: 1px solid #bbb !important;
  text-align: left !important;
}

/*ændrer i tabel celler*/
.reveal .slides section table td {
  padding: 8px 12px !important; 
  border-bottom: 1px solid #ddd !important;
  text-align: left !important;
}


/*til at quote ting*/
.pf-box {
  font-size: 1.4em;
  font-style: italic;
  line-height: 1.4;
  margin: 30px auto;
  padding: 25px 35px;
  max-width: 900px;
  background: #f5f7fa;
  border-left: 6px solid #1f4e79;
  border-radius: 8px;
  text-align: left;
}

</style>
```

## Introduction

-   Presynaptic neuronal protein alpha-Synuclein

-   Aggregation between nerve cells -\> inhibition of transmission

-   2 Projects using SAA (α-synuclein seed amplification assays)

<br>

**General focus:**

::: pf-box
Does one of the methods perform better than the other, and which is one more efficient?
:::

## Materials and Methods

**Materials:**

-   PPMI (Parkinson's Progression Markers Initiative) database

-   3 replicates of SAA (cerebrospinal fluid)

-   Monitors the aggregation by measuring fluorescence intensity over time

-   Sigmoidal curve: fmax, auc, ttt

-   Set of critera for positive/negative/inconclusive

<br>

**Methods:**

-   Tidyverse to visualize the data

-   Tools:

-   Quality check

## Methods: Tidying

::::: columns
::: {.column width="60%"}
-   Tidy data makes it much easier to handle

-   Requirements for tidy data

    -   Each column is one variable (Not the case initially)

    -   Each row is one observation

    -   Each cell is one value <br> <br> <br>

![](images/pivotlonger_example.png){fig-align="left" width="650"}
:::

::: {.column width="40%"}
![](images/tidy_data_flow.png){fig-align="right" width="300"}
:::
:::::

## Methods: Augmenting

-   Days from baseline

    -   Calculated from rundates

-   Mean of fmax for each visit

-   Our own SAA_result

## Descriptive

::::: columns
::: {.column width="50%"}
-   Two projects: 155 (150h) and 237 (24h)
-   1300 individuals, almost 1900 observations

<br>

-   2 functions, overview of high/low values

<br> <br>

-   Frequency of instrument used
:::

::: {.column width="50%"}
![](../results/04_project_distribution.png){width="600"}

![](../results/04_instruments_used.png){width="600"}
:::
:::::

# Results

## SAA quality check

:::::::: rows
:::::: row
::::: columns
::: {.column width="50%"}
-   SAA result and SAA custom quality check

-   A non-mentioned criteria?

-   Low fmax (200–600 RFU), huge, moderate

-   Hard to know for sure
:::

::: {.column width="50%"}
|              |                                   |
|--------------|-----------------------------------|
| **Result**   | **Project 155**                   |
| Positive     | All replicates Fmax ≥ 5,000 RFU   |
| Negative     | 0 or 1 replicate Fmax ≥ 5,000 RFU |
| Inconclusive | 2 replicates Fmax ≥ 5,000 RFU     |
:::
:::::
::::::

::: row
![](../results/05_mismatched_saa_plot_log.png){width="3000"}
:::
::::::::

<!-- -->

## SAA results

![](../results/06_saa_result_dist.png)

## Overlap ting

-   

## Inconsistencies in the two projects (replicates)

-   Can standard deviations in replicates say something about whether one project is better than the other?

![](../results/07_sd_by_project.png){width="2000"}

| Project | Mean SD | Median SD | IQR    |
|---------|---------|-----------|--------|
| **155** | 24,066  | 22,198    | 26,131 |
| **237** | 10,386  | 5,662     | 6,470  |

## Instruments

-   Can the instruments explain some of these differences?

![](../results/07_fmax_raw_rep_inst.png){width="3000"}

## Patients over time

Question: Does the signal become stronger further into disease progression?

::: panel-tabset
### Attempt at linear model

![](../results/08_fmax_over_time_lm.png)

-   Only for project 237 above

    -   Not necessarily comparable fmax mean values

    -   Project 155 only had close to baseline measurements

-   No connection

-   Note: Days from baseline is a not actually a measure of disease progression...

### Residual plot

![](../results/08_fmax_over_time_resid.png)

### Subset of patients

![](../results/08_fmax_over_time_top12.png)

-   Patient variation, if any connection at all

-   We also looked at more patients
:::

# Last notes/conclusions

**24-hour assay (237) vs 150-hour assay (155):**

::: pf-box
Does one of the methods perform better than the other, and which is one more efficient?
:::

-   Project **237:** Fast, accurate, clear separation, consistent

-   Healthy controls for better assessment
